Heparin Prowess: Favorable Vascular-Immune Reprogramming in Pancreatic Cancer

Clin Cancer Res. 2023 Jul 5;29(13):2348-2350. doi: 10.1158/1078-0432.CCR-23-0346.

Abstract

Several approaches for overcoming immunotherapy resistance in pancreatic and colorectal cancer syngeneic models were assessed using heparin and immunotherapy. Beneficial responses were attributed to heparin-induced vascular normalization, ensuing CD8+ T-cell infiltration, and M1 macrophage polarization, suggesting the potential for heparin-anchored therapies in cold tumors such as pancreatic cancer. See related article by Wei et al., p. 2525.

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Anticoagulants
  • CD8-Positive T-Lymphocytes / immunology
  • Heparin* / therapeutic use
  • Humans
  • Immunotherapy
  • Microcirculation
  • Pancreatic Neoplasms* / drug therapy
  • Pancreatic Neoplasms* / immunology

Substances

  • Heparin
  • Anticoagulants